6801. 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.
作者: Ashesh B Jani.;Eduard Schreibmann.;Subir Goyal.;Raghuveer Halkar.;Bruce Hershatter.;Peter J Rossi.;Joseph W Shelton.;Pretesh R Patel.;Karen M Xu.;Mark Goodman.;Viraj A Master.;Shreyas S Joshi.;Omer Kucuk.;Bradley C Carthon.;Mehmet A Bilen.;Olayinka A Abiodun-Ojo.;Akinyemi A Akintayo.;Vishal R Dhere.;David M Schuster.
来源: Lancet. 2021年397卷10288期1895-1904页
Molecular imaging is increasingly used to guide treatment decisions and planning in prostate cancer. We aimed to evaluate the role of 18F-fluciclovine-PET/CT in improving cancer control compared with conventional imaging (bone scan and either CT or MRI) alone for salvage postprostatectomy radiotherapy.
|